Form D · Biotechnology

Chemomab Therapeutics Ltd.

Tel Aviv, L3 · CIK 0001534248

Offering snapshot reported Aug 9, 2024 · SEC filing

Reported sold
$10M
Offering amount: $10M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 29, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 9, 2024Initial$10,000,000No comparison10SEC filing
Mar 30, 2021Initial$45,446,544No comparison26SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$400K
Finders' fees
$0
Form D file number
021-521145

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Oppenheimer & Co. Inc.249

Source: Form D, filed Aug 9, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Arnon Aharon Executive
Moses Charles Alan Director
Neil Harris Cohen Director
Nissim Darvish Director
Sigal Fatal Executive
Sigal Fattal Executive
Matthew Frankel Executive
Joel Michael Maryles Director
Adi Mor Director, Executive
Adi Mor George Director, Executive
Alan Charles Moses Director
Claude Nicaise Director
Jill Quigley Director
Stephen P Squinto Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Kiryat Atidim, Building 7
Tel Aviv, L3, 6158002